Product Development Progress - The company announced that its self-developed breast cancer NGS companion diagnostic kit has successfully entered the priority review channel of the National Medical Products Administration (NMPA) Medical Device Technology Review Center (CMDE), which may accelerate the approval process for the product in the domestic market [2] Financial Performance - According to the Q2 2025 financial report released on September 8, 2025, the company achieved a revenue growth of 10% year-on-year, with net losses narrowing by 91%. The gross margin improved to 72.8%, indicating significant operational efficiency improvements [3] Stock Performance - On January 5, 2026, the company's stock price experienced a notable increase, rising by 6.71% in a single day, closing at $21.00 per share [4]

Core Insights - Southbound funds increased their holdings in MicroPort Medical (00853.HK) by 1.4415 million shares on February 13, with net increases recorded on 4 out of the last 5 trading days, totaling 676,500 shares [1] - Over the past 20 trading days, there have been net increases on 15 days, amounting to 20.3817 million shares [1] - Currently, southbound funds hold 926 million shares of MicroPort Medical, representing 48.26% of the company's total issued ordinary shares [1] Company Overview - MicroPort Medical Science Co., Ltd. is primarily engaged in the sales, production, research, and development (R&D) of medical devices [1] - The company operates through eight divisions, including: - Cardiovascular Interventional Business: Products include implantable devices and access devices [1] - Orthopedic Medical Devices: Focuses on joint reconstruction and spinal devices [1] - Cardiac Rhythm Management (CRM): Includes pacemakers and defibrillators [1] - Aortic and Peripheral Vascular Interventional Business: Features products like the "L-REBOA" aortic occlusion balloon [1] - Neurointerventional Business: Involves products for carotid artery atherosclerosis and coils [1] - Structural Heart Disease Business: Engages in transcatheter aortic valve implantation [1] - Surgical Robotics Business: Manufactures and develops surgical robotic devices [1] - Surgical Medical Devices Business: Focuses on the manufacturing and R&D of surgical medical devices [1]

Core Viewpoint - Southbound funds increased their holdings in Chuangli Medical (01858.HK) by 61,000 shares on February 13, 2023, despite a net reduction of 338,800 shares over the past five trading days [1] Group 1: Southbound Fund Activity - In the last five trading days, there were three days of net reductions in holdings by southbound funds, totaling 338,800 shares [1] - Over the past 20 trading days, there were ten days of net reductions, amounting to 246,800 shares [1] - As of now, southbound funds hold 41,125,800 shares of Chuangli Medical, representing 43.21% of the company's issued ordinary shares [1] Group 2: Company Overview - Beijing Chuangli Zhengda Medical Device Co., Ltd. primarily engages in the research, development, production, and sales of implantable orthopedic medical devices [1] - The company's main products include joint prosthetics, spinal implants, trauma products, sports medicine products, platelet-rich plasma (PRP) products, oral products, and surgical robots [1] - Joint prosthetics cover four major human joints: hip, knee, shoulder, and elbow, with products sold in both domestic and international markets [1]

Group 1 - Ningbo Tianyi Medical Equipment Co., Ltd. has invested 50 million RMB to establish Ningbo Tianyi Medical Technology Co., Ltd., holding 100% of the shares [1] - Ningbo Tianyi Medical Technology Co., Ltd. was founded on December 19, 2024, with a registered capital of 50 million RMB and is located in Ningbo City [1] - The company is involved in various sectors including the production and sale of medical devices, pharmaceuticals, and health consulting services [1] Group 2 - The company is authorized to engage in the production of first, second, and third-class medical devices, as well as the production and wholesale of pharmaceuticals [1] - Additional activities include technical services, technology development, and the sale of rubber and plastic products [1] - The company is also permitted to conduct import and export activities related to goods and technology [1]

Group 1 - The core announcement is that MicroPort Cardiac Rhythm Management (MicroPort) has received a favorable review from the National Medical Products Administration (NMPA) for its new generation implantable cardioverter-defibrillator (ICD) TILEN/EYLEN, which is expected to enter the innovative medical device special review process [1] - TILEN/EYLEN is anticipated to be the first domestically approved MRI-safe ICD with independent intellectual property rights, addressing a significant technological gap in the domestic market [1] - The device features automatic MRI functionality, remote follow-up capabilities using low-power Bluetooth technology, and an industry-leading lifespan, which collectively aim to enhance patient comfort, compliance, and reduce long-term economic burdens [1] Group 2 - Sudden Cardiac Death (SCD) is a major global cause of mortality, and ICDs have been proven to be the most effective preventive measure against SCD, restoring normal heart rhythm during life-threatening arrhythmias [2] - The PLATINIUM series ICD products have already received NMPA approval in September 2024, marking the first domestically approved ICD, thus providing more treatment options for SCD in China and promoting the local development and application of high-energy defibrillator devices [2] - The entry of TILEN/EYLEN into the NMPA green channel is expected to accelerate the domestic production process of MRI-safe ICDs [2]

Core Viewpoint - MicroPort Cardiac Rhythm Management-B (02160) has announced that its next-generation implantable cardioverter-defibrillator (ICD) TILEN/EYLEN is set to enter the NMPA's special review process, potentially becoming the first domestically approved MRI-safe ICD with independent intellectual property rights in China [1][2] Group 1: Product Development - TILEN/EYLEN is a core product of a national key research and development project initiated by the Ministry of Science and Technology, aimed at filling a technological gap in the domestic market [1] - The ICD features automatic MRI functionality, significantly reducing patient discomfort caused by asynchronous modes and simplifying the MRI scanning process [1] - It includes remote follow-up capabilities based on low-power Bluetooth technology, enhancing patient compliance through a complete solution supported by domestic data centers [1] Group 2: Market Impact - Sudden Cardiac Death (SCD) is a leading cause of death globally, and ICDs have been proven to be the most effective measure for preventing SCD by restoring normal heart rhythm during life-threatening arrhythmias [2] - The company's PLATINIUM™ series ICD products received NMPA approval in September 2024, marking the first domestically approved ICD and providing more options for SCD prevention and treatment for Chinese patients [2] - The entry of TILEN/EYLEN into the NMPA green channel is expected to accelerate the domestic production process of MRI-safe ICDs [2]

Group 1 - The National Medical Products Administration (NMPA) has announced the acceptance of the new generation implantable cardioverter-defibrillator (ICD) TILEN/EYLEN for special review, which is expected to be the first domestically approved MRI-safe ICD with independent intellectual property rights [1] - TILEN/EYLEN is a core product of a national key research and development project, aiming to fill the technological gap in the domestic market, featuring advantages such as automatic MRI functionality, remote follow-up capabilities, and industry-leading lifespan [1] - The ICD market is significant as sudden cardiac death (SCD) is a major global cause of death, and ICDs have been proven to be the most effective measure for preventing SCD, providing critical treatment during life-threatening arrhythmias [2] Group 2 - The company's PLATINIUM series ICD products received NMPA approval in September 2024, marking the first domestically approved ICD, thus expanding treatment options for SCD in China and promoting the local development and application of high-energy defibrillator devices [2] - The entry of TILEN/EYLEN into the NMPA green channel is expected to accelerate the domestic production process of MRI-safe ICDs [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 MicroPort CardioFlow Medtech Corporation 微創心通醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：2160） 自願公告 — 植入式心律轉復除顫器進入 創新醫療器械特別審查程序 本公告乃由微創心通醫療科技有限公司（「本公司」，連同其附屬公司統稱「本 集團」）自願作出，以知會本公司股東及潛在投資者有關本集團最新業務和新 產品開發進展。 本公司董事會（「董事會」）欣然宣佈，近日，國家藥品監督管理局「NMPA」醫療 器械技術審評中心發佈《創新醫療器械特別審查申請審查結果公示（2026年第3 號）》，擬同意本集團旗下新一代植入式心律轉復除顫器（「ICD」）TILEN/EYLEN （泰然╱怡然）進入創新醫療器械特別審查程序（「NMPA綠色通道」）。據此， TILEN/EYLEN（泰然╱怡然）有望成為國內首款獲批的具備自主知識產權的 ...

Group 1 - The company MicroPort Scientific Corporation (02252) has received approval from the Hong Kong Stock Exchange for the listing and trading of 5.9898 million H shares, which are to be converted and listed [1] - The conversion and listing will involve a total of 5.9898 million non-listed shares held by two shareholders, representing approximately 0.5808% of the total issued shares of the company as of the announcement date [1]

Core Viewpoint - Baird Medical (BDMD.OQ) has experienced a significant decline in stock price over the past week, raising market concerns about its financial health and investor confidence [1][2] Group 1: Stock Performance - On February 12, 2026, the closing price was $0.80, with a daily drop of 4.76%, reaching a historical low of $0.77 during intraday trading, and a total trading volume of $85,200 [1] - Year-to-date, the cumulative decline has reached 41.17%, indicating a severe downturn in stock performance [1] - The stock experienced a 13.04% drop over the past week, with a trading range volatility of 31.30% [1] Group 2: Market Context - On February 11, 2026, the stock price fell by over 8% without any major announcements from the company, reflecting investor concerns over its ongoing losses [2] - The medical device sector saw a slight increase of 0.07% on the same day, while the Nasdaq index decreased by 0.04%, highlighting the company's underperformance compared to its peers [2] - The company's price-to-earnings ratio (TTM) is negative at -7.55, indicating a continued state of losses and low liquidity, which can lead to significant price fluctuations [1]